FORT LAUDERDALE, Fla., Mar 29, 2010 (BUSINESS WIRE) --Donna E. Shalala, Ph.D., President of the University of Miami and former U.S. Secretary of Health and Human Services, has been nominated to a newly created seat on the Board of Directors of MEDNAX, Inc. (NYSE: MD).

MEDNAX announced Dr. Shalala's nomination, as well as the nomination of 10 incumbent directors for re-election to the Company's Board of Directors, in its proxy statement filed March 26, 2010.

"We look forward to Dr. Shalala's contributions to our Board as we continue to execute on our proven growth strategy, one that is changing healthcare delivery in this nation, adding value to patients cared for by physicians practicing as part of our national group," said Roger J. Medel, M.D., Chief Executive Officer of MEDNAX, Inc. "Her proven leadership in healthcare policy, financing and administration and in advancing the expansion of academic institutions in this country brings unique insight to MEDNAX."

Dr. Shalala has served as the President of the University of Miami since 2001, where she has helped to solidify the institution's position among the nation's top research universities.

From 1993 until 2001, Dr. Shalala was the U.S. Secretary of Health and Human Services, where she directed a variety of programs including Social Security, Medicare, Medicaid, Child Care and Head Start, the Public Health Service, the National Institutes of Health, the Centers for Disease Control and Prevention and the Food and Drug Administration.

Dr. Shalala served as Chancellor and professor of Political Science at the University of Wisconsin-Madison from 1987 to 1993 and as President and Political Science professor at Hunter College from 1980 to 1987. From 1977 to 1980, Dr. Shalala served as Assistant Secretary of the Department of Housing and Urban Development.

Dr. Shalala is also a director of Gannett Co., Inc. and Lennar Corporation, a Trustee of the Henry J. Kaiser Family Foundation, a member of the Council on Foreign Relations, and a member of the Institute of Medicine of the National Academy of Sciences.

MEDNAX's Annual Meeting of Shareholders is scheduled for Thursday, May 6, 2010, at 10 a.m. Eastern Time, at the Hyatt Regency Bonaventure in Weston, Florida. At the meeting, shareholders will be asked to elect a slate of 11 Directors, including Roger J. Medel, M.D., Cesar L. Alvarez, Waldemar A. Carlo, M.D., Michael B. Fernandez, Roger K. Freeman, M.D., Paul G. Gabos, Dany Garcia, Pascal J. Goldschmidt, M.D., Manuel Kadre, Dr. Shalala and Enrique J. Sosa, Ph.D., each for a term expiring at the next annual meeting or until his or her successor has been duly elected and qualified; and to ratify the appointment of PricewaterhouseCoopers LLP as MEDNAX's independent registered certified public accounting firm for the 2010 fiscal year.

ABOUT MEDNAX

MEDNAX, Inc., is a national medical group that comprises the nation's leading provider of neonatal, maternal-fetal and pediatric physician subspecialty services as well as anesthesia services. Physicians and advanced practitioners practicing as part of MEDNAX are reshaping the delivery of care within their specialties and subspecialties, using evidence-based tools, continuous quality initiatives and clinical research to enhance patient outcomes and provide high-quality, cost-effective care. Pediatrix Medical Group, a unit of MEDNAX, was founded in 1979 and now includes neonatal physicians who provide services at more than 275 neonatal intensive care units, who collaborate with affiliated maternal-fetal medicine, pediatric cardiology and pediatric intensivist physician subspecialists to provide a clinical care continuum. Pediatrix is also the nation's largest provider of newborn hearing screens. In 2007, the Company expanded into anesthesia services. Today, American Anesthesiology includes more than 550 anesthesiologists and advanced practitioners. MEDNAX, through its affiliated professional corporations, employs more than 1,450 physicians in 33 states and Puerto Rico. Additional information is available at www.mednax.com.

Certain statements and information in this press release may be deemed to contain forward-looking statements which may include, but are not limited to, statements relating to our objectives, plans and strategies, and all statements, other than statements of historical facts,that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as "believe", "hope", "may", "anticipate", "should", "intend", "plan", "will", "expect", "estimate", "project", "positioned", "strategy" and similar expressions, and are based on assumptions and assessments made by MEDNAX's management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and MEDNAX undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that couldcause actual results, developments, and business decisions to differ materially from forward-looking statements are described in MEDNAX's most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled "Risk Factors", as well MEDNAX's current reports on Form 8-K,filed with the Securities and Exchange Commission.

SOURCE: MEDNAX, Inc.

MEDNAX, Inc.
Bob Kneeley, 954-384-0175, x-5300
Director, Investor Relations
bob_kneeley@mednax.com